Search
A low-dose radiation approach could help more patients avoid side effects of treatment for head and neck cancer.
Cell biologist Michael Overholtzer will succeed DNA replication expert Ken Marians.
Seven students have successfully defended their dissertations and will receive their PhD degrees at commencement on May 18.
Learn more about a new radiopharmaceutical treatment for prostate cancer approved by the FDA for more patients.
Eric Alonzo successfully defended his thesis in September 2011. He completed his dissertation research in the laboratory of Dr. Derek Sant'Angelo in the Immunology Program.
Learn how intermittent fasting is being explored by researchers for possible use in cancer treatment and prevention, including breast cancer.
The Gerstner Sloan Kettering Graduate School of Biomedical Sciences (GSK) at Memorial Sloan Kettering Cancer Center (MSK) today announced The Pat and Ian Cook Doctoral Program in Cancer Engineering, made possible by a generous gift of $15 million from Pat and Ian Cook.
The experimental drug selumetinib is the first targeted therapy to demonstrate significant clinical benefit for patients with metastatic uveal melanoma, according to new Memorial Sloan Kettering Cancer Center research presented at the 49th annual meeting of the American Society of Clinical Oncology.
MSK researchers used the genome-editing tool CRISPR to create more potent chimeric antigen receptor (CAR) T cells that don't tire as easily when attacking cancer cells. The unexpected findings were published in the journal Nature on February 22 and underscore the potential of genome editing to advance immunotherapy for cancer.
On November 10, 2025, hundreds gathered in the Mortimer B. Zuckerman Research Center for the “MSK Innovation with Lasting Impact Summit: Entrepreneurship & Innovation at MSK,” at an event that brought together laboratory and clinical researchers, digital health innovators, healthcare executives, and investors.